These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23973115)

  • 1. Attributable costs of differentiated thyroid cancer in the elderly Medicare population.
    Boltz MM; Hollenbeak CS; Schaefer E; Goldenberg D; Saunders BD
    Surgery; 2013 Dec; 154(6):1363-9; discussion 1369-70. PubMed ID: 23973115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
    Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
    J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Cutoff Age for Predicting Mortality Associated with Differentiated Thyroid Cancer.
    Kim SJ; Myong JP; Suh H; Lee KE; Youn YK
    PLoS One; 2015; 10(6):e0130848. PubMed ID: 26102084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients.
    Oyer SL; Fritsch VA; Lentsch EJ
    Ann Otol Rhinol Laryngol; 2014 Feb; 123(2):94-100. PubMed ID: 24574464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Tumor Size on Risk of Metastatic Disease and Survival for Thyroid Cancer: Implications for Biopsy Guidelines.
    Nguyen XV; Roy Choudhury K; Tessler FN; Hoang JK
    Thyroid; 2018 Mar; 28(3):295-300. PubMed ID: 29373949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of papillary thyroid cancer surveillance.
    Wang LY; Roman BR; Migliacci JC; Palmer FL; Tuttle RM; Shaha AR; Shah JP; Patel SG; Ganly I
    Cancer; 2015 Dec; 121(23):4132-40. PubMed ID: 26280253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.
    Bhattacharyya N
    Otolaryngol Head Neck Surg; 2003 Jan; 128(1):115-23. PubMed ID: 12574769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid.
    Oda H; Miyauchi A; Ito Y; Sasai H; Masuoka H; Yabuta T; Fukushima M; Higashiyama T; Kihara M; Kobayashi K; Miya A
    Endocr J; 2017 Jan; 64(1):59-64. PubMed ID: 27667647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial attributable cost and economic burden of clinically-relevant differentiated thyroid cancer: A health care service provider perspective.
    Lang BH; Wong CK; Chan CT
    Eur J Surg Oncol; 2015 Jun; 41(6):758-65. PubMed ID: 25680952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicular variant papillary thyroid carcinoma in a pediatric population.
    Lerner J; Goldfarb M
    Pediatr Blood Cancer; 2015 Nov; 62(11):1942-6. PubMed ID: 26131690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recovery rate in differentiated thyroid cancer. Experiences of one of the Hungarian clinical centers].
    Szujó S; Bajnok L; Bódis B; Nemes O; Rucz K; Mezősi E
    Orv Hetil; 2018 Jun; 159(22):878-884. PubMed ID: 29806478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma.
    Zaydfudim V; Feurer ID; Griffin MR; Phay JE
    Surgery; 2008 Dec; 144(6):1070-7; discussion 1077-8. PubMed ID: 19041020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of surgical resection extension on outcome for primary well-differentiated thyroid cancer-a retrospective analysis.
    Muller S; Senne M; Kirschniak A; Königsrainer A; Bares R; Falch C
    World J Surg Oncol; 2017 Oct; 15(1):190. PubMed ID: 29065879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annual financial impact of well-differentiated thyroid cancer care in the United States.
    Lubitz CC; Kong CY; McMahon PM; Daniels GH; Chen Y; Economopoulos KP; Gazelle GS; Weinstein MC
    Cancer; 2014 May; 120(9):1345-52. PubMed ID: 24481684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of Medicare Costs for Elderly Patients With Oral Cavity and Pharyngeal Cancers.
    Hollenbeak CS; Kulaylat AN; Mackley H; Koch W; Schaefer EW; Goldenberg D
    JAMA Otolaryngol Head Neck Surg; 2015 Jul; 141(7):628-35. PubMed ID: 26042925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical picture of differentiated thyroid carcinoma in the T1 stage].
    Czarniecka A; Włoch J; Lange D
    Wiad Lek; 2001; 54 Suppl 1():225-33. PubMed ID: 12182030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
    Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
    Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Raue F; Frank-Raue K
    Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
    Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
    Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.